PD-144418 [Ligand Id: 10731] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL4088272 |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| α2A-adrenoceptor/Alpha-2a adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913] | ||||||||
| ChEMBL | Activity of compound against Alpha-2A (ADRA2A) adrenergic receptor by displacement of [3H]-rauwolscine | B | 5.08 | pKi | 8317.64 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| α2B-adrenoceptor/Alpha-2b adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1942] [GtoPdb: 26] [UniProtKB: P18089] | ||||||||
| ChEMBL | Activity of compound against Alpha 2B (ADRA2B) adrenergic receptor by displacement of [3H]-rauwolscine | B | 4.69 | pKi | 20417.38 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| α2C-adrenoceptor/Alpha-2c adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1916] [GtoPdb: 27] [UniProtKB: P18825] | ||||||||
| ChEMBL | Activity of compound against Alpha 2C (ADRA2C) adrenergic receptor by displacement of [3H]-rauwolscine | B | 5 | pKi | 10000 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| M1 receptor/Muscarinic acetylcholine receptor M1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL216] [GtoPdb: 13] [UniProtKB: P11229] | ||||||||
| ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M1 (CHRM1) by displacement of 3H-QNB | B | 4.5 | pKi | >31622.78 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| M2 receptor/Muscarinic acetylcholine receptor M2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL211] [GtoPdb: 14] [UniProtKB: P08172] | ||||||||
| ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M2 (CHRM2) by displacement of 3H-QNB | B | 4.62 | pKi | 23988.33 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| M3 receptor/Muscarinic acetylcholine receptor M3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL245] [GtoPdb: 15] [UniProtKB: P20309] | ||||||||
| ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M3 (CHRM3) by displacement of 3H-QNB | B | 4.62 | pKi | 23988.33 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| M4 receptor/Muscarinic acetylcholine receptor M4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1821] [GtoPdb: 16] [UniProtKB: P08173] | ||||||||
| ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M4 (CHRM4) by displacement of 3H-QNB | B | 4.61 | pKi | 24547.09 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| M5 receptor/Muscarinic acetylcholine receptor M5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2035] [GtoPdb: 17] [UniProtKB: P08912] | ||||||||
| ChEMBL | Activity of compound against Muscarinic acetylcholine receptor M5 (CHRM5) by displacement of 3H-QNB | B | 4.55 | pKi | 28183.83 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| Sigma-1 receptor in Guinea pig (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4153] [UniProtKB: Q60492] | ||||||||
| ChEMBL | Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane after 150 mins by liquid scintillation counting method | B | 8.37 | pKi | 4.3 | nM | Ki | J Med Chem (2018) 61: 372-384 [PMID:29220177] |
| σ2/Sigma intracellular receptor 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4105907] [GtoPdb: 2553] [UniProtKB: Q5BJF2] | ||||||||
| ChEMBL | Binding affinity to human sigma 2 receptor | B | 5.86 | pKi | 1377 | nM | Ki | Bioorg Med Chem (2022) 73: 117032-117032 [PMID:36202063] |
| ChEMBL | Displacement of [3H]-DTG from the Sigma2 receptor | B | 6.1 | pKi | 794.33 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| σ2 in Mouse [GtoPdb: 2553] [UniProtKB: Q8VD00] | ||||||||
| GtoPdb | Displacement of [3H]DTG from sigma2 sites on membranes from NG 108-15 neuroblastoma X glioma rat/mouse hybrid cells | - | 5.86 | pKi | 1377 | nM | Ki | Neuropharmacology (1997) 36: 51-62 [PMID:9144641] |
| sigma non-opioid intracellular receptor 1/Sigma opioid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL287] [GtoPdb: 2552] [UniProtKB: Q99720] | ||||||||
| ChEMBL | Displacement of [3H]-pentazocin from the Sigma1 receptor | B | 8.7 | pKi | 2 | nM | Ki | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing |
| ChEMBL | Binding affinity to human sigma 1 receptor | B | 10.1 | pKi | 0.08 | nM | Ki | Bioorg Med Chem (2022) 73: 117032-117032 [PMID:36202063] |
| sigma non-opioid intracellular receptor 1 in Mouse [GtoPdb: 2552] [UniProtKB: O55242] | ||||||||
| GtoPdb | Displacement of [3H](+)-pentazocine from sigma1 sites on membranes from NG 108-15 neuroblastoma X glioma rat/mouse hybrid cells | - | 10.1 | pKi | 0.08 | nM | Ki | Neuropharmacology (1997) 36: 51-62 [PMID:9144641] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
